← Human Trials & Peer-Reviewed Studies
Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial
Plain-language guide to PMID 35484607 (2022): placebo-controlled randomized controlled trial study of Exenatide, low blood pressure and orthostatic hypotension.
Key Facts
- PMID
- 35484607
- Journal
- Cardiovascular diabetology
- Year
- 2022
- Study type
- Randomized Controlled Trial
- Authors
- van Ruiten CC et al. (8 authors)
- DOI
- 10.1186/s12933-022-01492-x
What This Study Did, in Plain Language
What Was Tested
Researchers studied Exenatide in the context of low blood pressure and orthostatic hypotension in this randomized controlled trial publication.
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) lower blood pressure (BP).
When SGLT2i and GLP-1RA are combined, synergistic effects on BP have been observed.
Who Took Part
The effect of treatments on estimates of: (1) plasma volume (calculated by Strauss formula, bioimpedance spectroscopy, hematocrit, (2) autonomic nervous system activity (heart rate variability), (3) arterial stiffness (pulse wave applanometry), (4) systemic hemodynamic parameters including peripheral vascular resistance, cardiac output and stroke volume (all derived from non-invasively systemic hemodynamic monitoring), and (5) natriuresis (24-hour urine collection) were assessed after 10 days and 16 weeks of treatment.
How the Study Was Run
The design is described as randomized and placebo-controlled.
Random assignment meant chance, not the researchers, decided who got Exenatide and who got the comparison, which limits bias.
A placebo (an inactive look-alike) gave the Exenatide group a baseline to be compared against.
The timeline in the abstract includes 10 days.
What Was Measured
Topics PubMed links to this paper include Benzhydryl Compounds, Blood Pressure, Diabetes Mellitus, Type 2, Exenatide, Glucosides, Hypoglycemic Agents and Sodium-Glucose Transporter 2 Inhibitors.
Author keywords: Autonomic balance, Dapagliflozin, GLP-1 receptor agonist, Hemodynamics, SGLT2 inhibitor and Type 2 diabetes.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of Exenatide in people with low blood pressure and orthostatic hypotension over 10 days.
Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2022 (Cardiovascular diabetology), a journal based in England.
More context: the Exenatide compound page, Low blood pressure and orthostatic hypotension research.
Our Notes on the Compound
Exenatide: A 39-amino-acid GLP-1 receptor agonist first identified in Gila monster venom; sold as Byetta and Bydureon for type 2 diabetes.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.